Ryan Mitteness

Jan 9, 2025 | jdsupra.com | Robert N. Freedman |Ryan Mitteness |Amanda Rose

The outlook for life sciences IPOs is showing renewed optimism heading into 2025, with market conditions becoming more constructive and regulatory environments potentially more favorable. Fenwick’s Amanda Rose, Rob Freedman, and Ryan Mitteness recently unpacked these developments—and what innovators can do to prepare to go public in 2025—alongside Morgan Stanley’s Ryuk Byun and Tedd Smith. Here are the essential insights for life sciences companies considering going public in 2025.

Jan 6, 2025 | jdsupra.com | Chelsea Anderson |Robert N. Freedman |Ryan Mitteness

This article is part of our series on clinical data considerations. Read How to Prepare for Disclosure. For publicly traded biotech companies, disclosing clinical trial data can be an exciting milestone as you build towards an exit or public offering—but disclosure is a double-edged sword. Disclosures can position your company favorably for investors, or it can invite serious regulatory scrutiny that delays your plans.

May 10, 2024 | jdsupra.com | Andrew T. Albertson |Ryan Mitteness |Ryan McRobert

Global demand for Tokenized Real-World Assets (RWAs) is growing rapidly in the decentralized finance (DeFi) community and traditional finance industry. Tokenized RWAs allow legal ownership or rights to traditionally illiquid assets to be digitalized and traded on digital platforms, leading to expedited settlements and potentially reduced operating costs.